Merck may be near NuvaRing settlement

Share this article:

Merck may be poised to settle lawsuits over its NuvaRing contraceptive for $100 million—a bargain, Bloomberg notes, compared to drugmakers such as Bayer, which has paid more than $1.6 billion over claims surrounding its birth control pills Yaz and Yazmin.

Women and families have sued the company, saying the drugmaker knew the contraceptive triggered a higher risk of heart attack and blood clots than competing products. Merck told Bloomberg that the proposed settlement is not an admission of wrongdoing and the company stands behind the contraceptive.

Ninety-five percent of the 3,800 plaintiffs need to agree to the settlement or Merck can walk away.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.